Cell Metabolism, volume 32, issue 2, pages 176-1870000
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Xiao-Jing Zhang
1
,
Juan‐Juan Qin
2
,
Cheng Xu
2
,
Lijun Shen
2
,
Yan-Ci Zhao
2
,
Yufeng Yuan
3
,
Lei Fang
4
,
Ming-Ming Chen
2
,
Huilin Yang
2
,
Liangjie Bai
4
,
Xiaohui Song
4
,
Lijin Lin
2
,
Meng Xia
4
,
Zhou Feng
5
,
Jianghua Zhou
2
,
Zhi-Gang She
2
,
Lihua Zhu
2
,
Xinliang Ma
6
,
Qingbo Xu
7
,
Ping Ye
8
,
Guohua Chen
9
,
Liming Liu
10
,
Weiming Mao
11
,
Youqin Yan
12
,
Bing Xiao
13
,
Zhigang Lu
14
,
Gang Peng
15
,
Mingyu Liu
16
,
Jun Yang
17
,
Luyu Yang
18
,
CHANGJIANG ZHANG
19
,
Haofeng Lu
20
,
Xigang Xia
21
,
Daihong Wang
22
,
Xiaofeng Liao
23
,
Xiang Wei
24
,
Bing-Hong Zhang
25
,
Xin Zhang
4
,
Juan Yang
2
,
Guang‐Nian Zhao
5
,
Peng Zhang
5
,
Peter P. Liu
26
,
Rohit S. Loomba
27
,
Yan‐Xiao Ji
5
,
Jiahong Xia
28
,
Yibin Wang
29
,
Jingjing Cai
30
,
Hongliang Li
19
9
Department of Neurology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430072, China
|
10
Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, China
|
11
Department of General Surgery, Huanggang Central Hospital, Huanggang 438000, China
|
12
Wuhan Seventh Hospital, Wuhan 430072, China
|
13
Department of Stomatology, Xiantao First People’s Hospital, Xiantao 433000, China
|
15
Department of Hepatobiliary and Pancreatic Surgery, Suizhou Central Hospital Affiliated to Hubei Medical College, Suizhou 441300, China
|
16
The Ninth Hospital of Wuhan City, Wuhan 430072, China
|
20
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Changjiang University, Jingzhou, China
|
21
Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou, China
|
22
Department of Hepatobiliary and Pancreatic Surgery, Xianning Central Hospital, Xianning, Hubei Province, China
|
Publication type: Journal Article
Publication date: 2020-08-01
Journal:
Cell Metabolism
scimago Q1
wos Q1
SJR: 11.406
CiteScore: 48.6
Impact factor: 27.7
ISSN: 15504131, 19327420
Molecular Biology
Cell Biology
Physiology
Abstract
Summary
Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.